Overview

Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate

Status:
Terminated

Trial end date:
2008-07-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in cancer cells. It may also help doctors understand how cancer cells respond to treatment with choline magnesium trisalicylate. PURPOSE: This pilot clinical trial is studying gene expression in cancer cells during chemotherapy and the safety of choline magnesium trisalicylate in treating patients with newly diagnosed acute myeloid leukemia.

Phase:

Phase 1

Details

Lead Sponsor:

Rutgers, The State University of New Jersey

Collaborator:

National Cancer Institute (NCI)

Treatments:

BB 1101
Choline
Choline magnesium trisalicylate
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Salicylates